VistaGen Therapeutics Company Presentation

www.vistagen.com 28 • Randomized, double-blind, placebo-controlled, multi-center monotherapy study • MDD patients with zero or 1 prior failure on a standard antidepressant • Twice a day administration of PH10 (3.2 P g or 6.4 P g) or placebo for 4 weeks • Rapid-onset potential within less than one week, potentially hours to days • Target enrollment, 150 (completed subjects) Primary Endpoint: Change in HAM-D-17 from baseline compared to placebo PH10 U.S. Phase 2B Development Plan for MDD Principal Investigator: Dr. Maurizio Fava, Harvard University